Skip to main content

Rosetta Genomics Stock Surges on Lung Cancer Dx Findings

NEW YORK (GenomeWeb News) – Rosetta Genomics' stock soared 72 percent in mid-afternoon trading on Nasdaq after announcing a successful clinical study on one of its lung cancer diagnostic tests.

The Rehovot, Israel-based company's share price rose $1.33 to $3.18 from yesterday's close of $1.85.

A joint study by the company and Johns Hopkins University showed that the firm's miRview squamous non-small cell lung cancer diagnostic accurately classified NSCLC samples from resection and from fine-needle aspirate cell blocks, Rosetta said.

The miRview test, offered in the US by Prometheus Laboratories under the brand name ProOnc, is a microRNA-based molecular assay that classifies NSCLCs using the expression level of a single microRNA biomarker.

Details of the research are set to be published in the January 15 issue of the American Association for Cancer Research’s journal Clinical Cancer Research.

Rosetta Genomics' CEO, Ken Berlin, said in a statement that the study validated the miRview test's "sensitivity, specificity, reproducibility, and overall reliability in helping physicians accurately make this critical lung cancer classification."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.